Showing 3991-4000 of 5558 results for "".
- Don't Forget Leprosy: Group Marks 150th Anniversary of Dr. Hansen's Discovery of M. lepraehttps://practicaldermatology.com/news/dont-forget-leprosy-group-marks-150th-anniversary-of-dr-hansens-discovery-of-m-leprae/2461573/The University of Bergen, Norway and Sasakawa Leprosy (Hansen's Disease) Initiative will mark the 150th anniversary of Dr. Gerhard Armauer Hansen's discovery of the leprosy bacillus, M. leprae, in 1873. They plan to hold an
- Neauvia Scores CE Marking Under the European Union’s New MDR for Facial Dermal Filler Linehttps://practicaldermatology.com/news/neauvia-scores-ce-marking-under-the-european-unions-new-mdr-for-facial-dermal-filler-line/2461564/Neauvia scored CE marking under the European Union’s new MDR (Medical Device Regulation) for its range of facial dermal fillers products, making it the first medical aesthetics business to receive such certification in Europe. The new regulation aims to create ‘a robus
- Kintor Pharma’s GT20029 Performs Well in Phase 1 Trial of Acne and Androgenetic Alopeciahttps://practicaldermatology.com/news/kintor-pharmas-gt20029-performs-well-in-phase-i-trial-of-acne-and-androgenetic-alopecia/2461559/Kintor Pharmaceutical Limited’s GT20029 was safe and well tolerated and had good pharmacokinetic characteristics in healthy people and people with androgenetic alopecia (AGA) or acne, according to a phase 1 clinical trial. GT20029 is the first topical PROTAC compound in the world
- Current Depression, Systemic Inflammation Linked in Psoriasishttps://practicaldermatology.com/news/current-depression-systemic-inflammation-linked-in-psoriasis/2461482/Current depression travels with increased neutrophils in psoriasis patients, especially females, finds research in the Journal of Investigative Dermatology. For the study, re
- Alphyn Biologics' Topical Performs Well in ADhttps://practicaldermatology.com/news/alphyn-biologics-topical-performs-well-in-ad/2461481/Alphyn B
- Promising and Consistent Topline Results Seen in Phase 3 Trial of Roflumilast in ADhttps://practicaldermatology.com/news/promising-and-consistent-topline-results-seen-in-phase-3-trial-of-roflumilast-in-ad/2461466/Arcutis Biotherapeutics, Inc.’s roflumilast met the key primary and secondary endpoints in the INT
- New Melanoma Immunotherapy Drugs Are Saving Liveshttps://practicaldermatology.com/news/new-melanoma-immunotherapy-drugs-are-saving-lives/2461462/New research suggest that the use of new pharmacological therapies is associated with a decrease in the melanoma mortality rate in the U.S. population. In the population-based cross-sectional study of patients with cutaneous melanoma from the Surveillance, Epidemiology, and E
- MyHealthTeam and Arcutis Biotherapeutics Launch Social Network for People Living with Seborrheic Dermatitishttps://practicaldermatology.com/news/myhealthteam-and-arcutis-biotherapeutics-launch-social-network-for-people-living-with-seborrheic-dermatitis/2461454/
- Celebrities Come Together for EB Research Partnershiphttps://practicaldermatology.com/news/celebrities-come-together-for-eb-research-partnership/2461453/EB Research Partnership
- Cosmetic Surgery Forum 2022 Kicks Off in Nashvillehttps://practicaldermatology.com/news/cosmetic-surgery-forum-2022-kicks-off-in-nashville/2461451/Now in its 14th year, the 2022 Cosmetic Surgery Forum is once again taking Nashville by storm with new faculty members, a new roundtable, and exciting new topics along with the frank discussions, candor, and live demos that attendees have come to expect. “CSF 2022 is our be